Solid Tumor Clinical Trials in Washington D.C., District of Columbia

9 studies are recruiting for solid tumor in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University Lombardi Cancer Center, Washington D.C., District of Columbia

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins University, Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

   This is an open-label phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation for pediatric and adult patients w…

   Stage

   Phase 1

   Ages

   1 to 70

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Run by

   Children's National Research Institute

   See if you can join NCT05238792 on ClinicalTrials.gov

4. A Study of ASP3082 in Adults With Advanced Solid Tumors

   This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University Hospital, Washington D.C., District of Columbia

   Locations

   66 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT05382559 on ClinicalTrials.gov

5. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

   The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

   Stage

   Phase 2

   Ages

   1 and older

   Site

   Children's National Hospital (Data Collection Only), Washington D.C., District of Columbia

   Locations

   16 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05985161 on ClinicalTrials.gov

6. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

7. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

   This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site-114, Washington D.C., District of Columbia

   Locations

   17 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06384807 on ClinicalTrials.gov

8. NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

   The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Run by

   Georgetown University

   See if you can join NCT05661201 on ClinicalTrials.gov

9. FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

   The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Locations

   19 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT06669117 on ClinicalTrials.gov